ADC clinical development at World ADC London 2027

Mar 8–11, 2027 London, UK ~700 attendees Website

15 organizations at World ADC London 2027 present work in clinical development: 9 drug developers, 3 academic, government and non-profit bodies and 3 technology and service providers. Between them they bring 21 presentations to the program. Most represented: Iksuda Therapeutics (2 on the program), Roche (2 on the program), University of Michigan (1 on the program). As of Oct 8, 2026.

All 75 organizations at World ADC London 2027 →

Showing 1–15 of 15 organizations

Organization	World ADC London 2027 Attendance
Iksuda Therapeutics Newcastle upon Tyne, UK
iksuda.com Biotech UK ADC developer with clinical programs and new payload classes, including a protein-alkylating payload.	Panel Tue Mar 9 9:30am CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies Plenary · with Araris Biotech, Oxford BioTherapeutics, Boehringer Ingelheim Clinical development Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with Queen's University Belfast, University of Michigan, Callio Therapeutics ADC discoveryClinical development Talk Novel ADC Designs Drive Improved Clinical Outcomes Clinical Lessons ADC discovery Workshop Thu Mar 11 1:00pm Leveraging Clinical Outcomes & Performance to Inform the Development of Novel ADC Design Post-conference workshop for Clinical Lessons · with Oxford BioTherapeutics ADC discovery
Roche Basel, Switzerland
roche.com Large pharma Pharmaceutical and diagnostics company developing medicines in oncology, immunology, neuroscience and other areas.	Workshop Thu Mar 11 1:00pm Designing the Next Generation of ADCs: Exploring Novel Constructs & Future Combination Strategies Post-conference workshop for Discovery Clinical development
University of Michigan Ann Arbor, MI
umich.edu Academic & healthcare Public research university in Ann Arbor, Michigan.	Talk Antibody Design for Effective ADCs: The Multiple Impacts of Fc Engineering Pre-conference: 5th Novel Conjugates Day Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with Queen's University Belfast, Callio Therapeutics, Iksuda Therapeutics ADC discoveryClinical development Workshop Thu Mar 11 9:00am Accelerating ADC Model Simulation with the Power of Artificial Intelligence & Machine Learning Post-conference workshop for Pre-Clinical & Translation
Oxford BioTherapeutics Oxford, UK
oxfordbiotherapeutics.com Biotech Oncology biotech discovering new cancer targets and developing antibody and ADC therapies, including the CD205-directed ADC OBT076.	Panel Tue Mar 9 9:30am CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies Plenary · with Iksuda Therapeutics, Araris Biotech, Boehringer Ingelheim Clinical development Workshop Thu Mar 11 1:00pm Leveraging Clinical Outcomes & Performance to Inform the Development of Novel ADC Design Post-conference workshop for Clinical Lessons · with Iksuda Therapeutics ADC discovery
Queen's University Belfast Belfast, UK
qub.ac.uk Academic & healthcare Public research university in Belfast, Northern Ireland.	Workshop Introduction to ADCs Day Pre-conference: Introduction to ADCs Day Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with University of Michigan, Callio Therapeutics, Iksuda Therapeutics ADC discoveryClinical development
Araris Biotech
ararisbiotech.com Biotech Swiss biotech developing antibody-drug conjugates, including multi-payload conjugates, with a linker that attaches payloads to unmodified antibodies.	Panel Tue Mar 9 9:30am CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies Plenary · with Iksuda Therapeutics, Oxford BioTherapeutics, Boehringer Ingelheim Clinical development
Bionavigen
bionavigen.com Consulting & other services Biopharmaceutical consultancy advising on drug discovery, preclinical and clinical development, and in-licensing of early-stage assets.	Talk Opportunities for Improving the Translational Safety of ADCs From NHPs to Humans Pre-conference: 4th Toxicity Day Clinical development
Boehringer Ingelheim Ingelheim, Germany
boehringer-ingelheim.com Large pharma Family-owned German pharmaceutical company with human and animal health medicines and an oncology pipeline.	Panel Tue Mar 9 9:30am CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies Plenary · with Iksuda Therapeutics, Araris Biotech, Oxford BioTherapeutics Clinical development
Callio Therapeutics
calliotx.com Biotech Clinical-stage biotech developing dual-payload ADCs, led by a HER2-targeted program, to counter tumor resistance.	Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with Queen's University Belfast, University of Michigan, Iksuda Therapeutics ADC discoveryClinical development
InduPro
induprotx.com Biotech Biotech developing antibody-drug conjugates against a new class of targets it calls TAPAs.	Talk TAPAs: A New Class of ADC Targets From Discovery to the Clinic Discovery Clinical development
Pfizer New York, NY
pfizer.com Large pharma Global pharmaceutical company whose oncology portfolio includes ADCs gained with Seagen, such as PADCEV.	Talk Treating Cancer From the Outside In: The Preclinical & Early Clinical Development of PF-08052667 for Non Muscle Invasive Bladder Cancer Preclinical & Translational Clinical development
SalubrisBio Gaithersburg, MD
salubrisbio.com Biotech Develops biologics for oncology and heart failure, including JK06, a biparatopic 5T4-targeted ADC with an MMAE payload.	Talk JK06 Biparatopic 5T4-Targeted MMAE ADC: Overcoming the Challenges of a Difficult Target Through Rational Design Clinical Lessons ADC discovery
VD Virgen de la Arrixaca University Hospital Murcia, Spain
Academic & healthcare Public university hospital in Murcia, Spain.	Talk Phase II/III ADC Data in Gynaecological Cancers & Ovarian Cancer: From Platinum Resistant Disease Towards Earlier Lines & Combination Regimens Pre-conference: 5th ADCs in Combination Day
Beacon Intelligence London, UK	◇Program Partner
beacon-intelligence.com Consulting & other servicesProgram Partner Drug development intelligence provider offering databases of drugs, clinical trials and deals, with ADC coverage, plus reports and consulting.	Also Presenting at the meeting, on no published session yet
Lonza Basel, Switzerland	◆Senior Partner
lonza.com/advanced-synthesis/bioconjugates CDMOs & CROsSenior Partner Swiss CDMO that has supported more than 100 ADC programs, covering antibodies, payload-linkers, conjugation and fill-finish, plus its GlycoConnect conjugation technology.	Talk Tue Mar 9 5:30pm Lonza’s GlycoConnect® Technology for Best-in-Class ADCs: Emerging Clinical Insights Plenary ADC discoveryClinical development